Form 4: Penumbra Director Sells Shares Under 10b5-1 Plan

Penumbra Inc. Director Thomas Wilder reported the sale of 372 common shares for $240.16 each, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Thomas Wilder, a Director of Penumbra Inc. (PEN), reported a transaction involving the sale of common stock.
• The transaction occurred on August 12, 2025.
• Wilder disposed of 372 shares of common stock at a price of $240.16 per share.
• The sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following this transaction, Thomas Wilder directly beneficially owns 372 shares of common stock, a portion of which is subject to vesting.
• Additionally, 4,506 shares are indirectly beneficially owned by the Thomas and Catharine Wilder Family Trust dated March 31, 2006.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can be perceived negatively, the execution under a Rule 10b5-1 plan indicates a pre-scheduled, non-discretionary transaction, mitigating any strong negative signal about the company's prospects.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent events or a change in outlook.

Negatives

• A director's sale of shares reduces insider ownership, which can sometimes be perceived negatively by investors.

Risks

• No specific operational or financial risks related to Penumbra Inc. are mentioned in this Form 4 filing.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Penumbra Inc.'s future performance or strategic direction.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive landscape analysis.

Related Party Transactions

• The Thomas and Catharine Wilder Family Trust, dated March 31, 2006, indirectly holds 4,506 shares of Penumbra common stock. Changes in beneficial ownership between direct and indirect holdings through this trust are exempt from Section 16 reporting under Rule 16a-13.

Stakeholder Impact

• Shareholders may perceive the director's sale as a slight reduction in insider alignment, although the pre-arranged nature under a Rule 10b5-1 plan mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale by a director under a Rule 10b5-1 trading plan. This type of transaction is typically for personal financial planning and does not usually signal a change in the company's fundamental outlook. The volume of shares sold is relatively small compared to the director's total holdings (including indirect), suggesting it's not a significant divestment. Therefore, the filing itself does not provide a strong basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it's a routine event.

Keywords

Penumbra Inc, PEN, Form 4, Insider Trading, Director Sale, Thomas Wilder, 10b5-1 Plan, Stock Transaction, Medical Devices